Evolution of Insulin: From Human to Analog
- 1 October 2014
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 127 (10) , S25-S38
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a reviewDiabetes, Obesity and Metabolism, 2013
- Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesDiabetes, Obesity and Metabolism, 2007
- Insulin‐associated weight gain in diabetes – causes, effects and coping strategiesDiabetes, Obesity and Metabolism, 2006
- A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 DiabetesDiabetes Care, 2006
- Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetesDiabetes Research and Clinical Practice, 2004
- The Treat-to-Target TrialDiabetes Care, 2003
- Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.Diabetes Care, 2000
- Insulin glargineThe Lancet, 2000
- Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.Diabetes Care, 2000
- Protamine InsulinJAMA, 1984